Emerging strategies in venous thromboembolism: a narrative review of pharmacological innovations Authors: Juan Ye, Kun Huang Published: 2026 ABSTRACT Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), is a major cause of preventable morbidity and mortality and is increasingly recognized as a chronic vascular disease. Although direct oral anticoagulants (DOACs) have simplified management, clinically important limitations remain. Major bleeding still occurs in roughly 2–4% of treated patients per year and clinically relevant nonmajor bleeding in 10–12%, while post-thrombotic syndrome (PTS) after proximal DVT and persistent functional limitation after PE continue to impair quality of life. This narrative review synthesizes emerging pharmacological strategies beyond conventional anticoagulation, with emphasis on the maturity of evidence and on the distinction between thromboprophylaxis, treatment of acute VTE, secondary prevention, and adjunctive thrombus-resolution approaches. Factor XI/activated factor XI (FXI/FXIa) inhibition is the most mature bleeding-sparing platform. In orthopedic thromboprophylaxis, abelacimab, FXI antisense oligonucleotides, milvexian, and osocimab reduced postoperative venous thrombosis with low bleeding signals, but most data still come from prophylaxis rather than treatment trials. By contrast, fibrinolysis-enhancing strategies targeting α2-antiplasmin, plasminogen activator inhibitor-1 (PAI-1), or thrombin-activatable fibrinolysis inhibitor (TAFI) seek to accelerate endogenous clot resolution and possibly reduce long-term disability, yet current clinical evidence remains early phase. Thrombo-inflammatory approaches targeting selectins or P-selectin glycoprotein ligand-1 (PSGL-1) have strong mechanistic rationale but limited direct clinical confirmation. Overall, the VTE pipeline is moving from broad suppression of coagulation toward mechanism-based strategies matched to specific clinical problems: bleeding-sparing anticoagulation, safer clot-resolution adjuncts, and therapies directed at vein wall injury. At present, FXI inhibition appears closest to clinical translation, whereas fibrinolysis-enhancing and thrombo-inflammatory approaches remain exploratory. Wider adoption will depend on phase 3 treatment outcomes, evidence in cancer and organ dysfunction, reversibility, cost-effectiveness, and integration into clinical guidelines. Background Venous thromboembolism (VTE), encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE), remains one of the most important causes of preventable cardiovascular morbidity and mortality. Its clinical importance is not limited to the acute event. After proximal DVT, 20–50% of patients develop post-thrombotic syndrome (PTS), and 5–10% experience severe manifestations such as venous ulceration, chronic pain, and substantial reduction in mobility [1]. After PE, persistent exertional limitation, dyspnea, or cardiopulmonary impairment is also common, and a subset of patients progress to chronic thromboembolic disease [2]. These observations support the modern view that VTE should not be regarded only as an acute clotting episode, but rather as a chronic vascular disorder with meaningful short-term and long-term consequences. The chronic-disease framing is reinforced by recurrence biology. In patients with a first unprovoked VTE, recurrence after discontinuation of anticoagulation remains substantial over subsequent years, which means that many patients face decisions about therapy duration long after the acute event has resolved [3]. The clinical burden therefore accumulates through recurrent thrombosis, bleeding from prolonged anticoagulation, and disability from unresolved thrombus or damaged venous and pulmonary vascular beds. This is why the therapeutic goal in modern VTE care is broader than short-term clot suppression alone: it is to reduce recurrence, minimize bleeding, and preserve long-term vascular function. Over the past decade, the treatment of VTE has been transformed by direct oral anticoagulants (DOACs). Compared with the historical heparin-to-warfarin strategy, DOACs provide fixed dosing, predictable pharmacokinetics, fewer food and drug interactions, and no need for routine laboratory monitoring. Large phase 3 trials established that they are at least as effective as vitamin K antagonists (VKAs) for acute DVT and PE, while reducing major bleeding and particularly intracranial hemorrhage [4]. As a result, DOACs are now the preferred anticoagulants for most patients with acute VTE and for many patients who require extended secondary prevention. Nevertheless, three major problems remain unresolved. First, bleeding remains the fundamental trade-off of anticoagulation. Even with DOAC therapy, major bleeding occurs in roughly 2–4% of patients per year and clinically relevant nonmajor bleeding in 10–12% [5]. In cancer-associated thrombosis (CAT), the balance is especially difficult: recurrence is high, but gastrointestinal and genitourinary tumors can bleed substantially on factor Xa inhibitors [6, 7]. Second, current evidence is thinner in the patients who often matter most in routine practice, including those with advanced kidney disease, significant hepatic impairment, marked frailty, and very advanced age [8]. Third, anticoagulants prevent thrombus propagation but do not reliably accelerate thrombus removal. Residual venous obstruction remains common despite apparently adequate therapy, and incomplete recanalization is linked to recurrence and chronic venous symptoms [9]. More aggressive clot-removal strategies such as catheter-directed thrombolysis can improve early patency in selected patients but at the cost of additional bleeding, and consistent prevention of late sequelae has been difficult to demonstrate [10]. These limitations have broadened the therapeutic agenda in VTE. New agents are being developed for at least three distinct purposes. One is to preserve antithrombotic efficacy while causing less bleeding, most notably by targeting factor XI (FXI), activated factor XI (FXIa), or selected components of the contact pathway. A second is to enhance endogenous fibrinolysis so that the existing clot resolves faster and more completely, potentially reducing residual obstruction, right-ventricular strain, or later disability. A third is to attenuate thrombo-inflammation and vein wall injury, processes increasingly recognized as central to thrombus propagation and to the development of PTS. These goals are complementary rather than interchangeable, and they should not be judged by the same clinical end points or in the same treatment settings. In this revised review, we therefore take a more selective and clinically hierarchical approach to emerging pharmacological therapy for VTE. We first summarize current standard care and the specific unmet needs that continue to drive drug development. We then examine intrinsic-pathway inhibition, fibrinolysis-enhancing strategies, and thrombo-inflammatory modulation, with explicit separation of data derived from postoperative thromboprophylaxis, acute VTE treatment, secondary prevention, and extracorporeal or device-associated thrombosis. Finally, we focus on high-risk populations (patients with cancer, older adults, and those with renal or hepatic impairment) to clarify what is currently known, what remains uncertain, and which strategies appear closest to clinical translation. Current standard anticoagulant therapy for VTE Conventional anticoagulation: heparins and vitamin K antagonists For decades, the standard treatment of VTE consisted of rapid-acting parenteral anticoagulation followed by a VKA. Unfractionated heparin (UFH) potentiates antithrombin and inhibits thrombin and factor Xa. Its short half-life, titratability, and reversibility make it useful in unstable patients, in those who may require urgent procedures, and in patients with severe renal impairment in whom drug accumulation is a concern [11]. Low-molecular-weight heparins (LMWHs) improved on this strategy by providing subcutaneous administration, more predictable pharmacokinetics, and less need for routine monitoring. LMWHs remain important in pregnancy, in selected patients with cancer, and in situations where short-term parenteral therapy is preferred [12, 13]. VKAs such as warfarin then became the dominant drugs for long-term secondary prevention. When the international normalized ratio (INR) is maintained within the therapeutic range, warfarin effectively reduces recurrent VTE [14]. However, its limitations are familiar: slow onset, frequent dose adjustment, multiple food and drug interactions, marked interpatient variability, and the need for repeated INR monitoring [15]. Bridging with heparin is required at initiation because early depletion of proteins C and S can transiently increase coagulability. Despite the emergence of DOACs, VKAs retain important niche roles, particularly in patients with mechanical heart valves and in those with high-risk antiphospholipid syndrome, where DOACs have proved inadequate or inferior [16–18]. The conventional regimen therefore remains highly effective but operationally cumbersome. Its legacy is important for two reasons. First, it provides the benchmark against which new anticoagulants are compared. Second, it reminds us that a “safer anticoagulant” must still be sufficiently potent to prevent recurrent symptomatic VTE, not merely to suppress laboratory markers of coagulation. That distinction is especially relevant when interpreting the early development of FXI-directed agents. Direct oral anticoagulants (DOACs) and their advantages Four DOACs are widely used for VTE management: dabigatran, a direct thrombin inhibitor, and the factor Xa inhibitors rivaroxaban, apixaban, and edoxaban. Across the pivotal phase 3 programs, these agents were noninferior to conventional therapy for prevention of recurrent symptomatic VTE [19–22]. Their widespread adoption was driven not only by similar efficacy but also by a more favorable safety profile, especially lower rates of intracranial hemorrhage and a meaningful reduction in major bleeding relative to VKAs [4]. In daily practice, the convenience of fixed dosing and the absence of routine coagulation monitoring made the change even more consequential than the relative-risk estimates alone might suggest. DOACs also simplified logistics. Rivaroxaban and apixaban can be started immediately with intensified initial oral dosing, avoiding prolonged heparin lead-in for many patients. All DOACs have relatively rapid onset and offset, predictable pharmacokinetics, and fewer interactions than warfarin, although clinically important interactions still occur through P-glycoprotein and, for some agents, CYP3A4 pathways [23, 24]. These practical advantages helped shift much of acute DVT care into the outpatient setting and enabled earlier discharge for selected low-risk PE patients [25]. Another important consequence of the DOAC era has been a change in how clinicians think about monitoring. Routine coagulation testing is usually unnecessary, but selective laboratory assessment still matters in special circumstances such as bleeding, urgent surgery, suspected nonadherence, or extremes of body size or organ function [24]. The need for less routine but more situational monitoring is relevant when comparing DOACs with future FXI-based drugs. A next-generation agent will be most attractive if it combines the simplicity of DOAC use with either an even wider safety margin or more stable performance in patients whose physiology makes current drug exposure unpredictable. Patient-reported outcomes also generally favor DOACs over warfarin, although the magnitude of benefit is variable across studies. A systematic review of patient-reported outcomes found consistently higher convenience and treatment satisfaction with DOACs, and a large survey in patients treated for VTE showed modestly higher treatment-satisfaction scores among DOAC users than among warfarin users [26, 27]. It is therefore more accurate to say that patients usually report greater convenience and at least slightly higher satisfaction with DOACs, rather than to imply a uniform or dramatic preference in every clinical context. DOACs have also expanded options for extended secondary prevention. In AMPLIFY-EXT, reduced-dose apixaban remained effective for preventing recurrent VTE with very low bleeding rates compared with placebo [28]. In EINSTEIN-CHOICE, rivaroxaban 10 mg daily outperformed aspirin with only a modest bleeding trade-off [29]. More recently, the RENOVE trial compared reduced-dose with full-dose DOAC regimens in higher-risk patients requiring extended therapy and found extremely low recurrence in both groups, with less major or clinically relevant bleeding in the reduced-dose arm [30]. These findings support dose de-intensification for selected patients after the highest-risk initial treatment period. Yet extended anticoagulation remains a compromise rather than a cure. Long-term prevention of recurrent VTE often comes at the cost of cumulative bleeding, and a substantial residual burden of symptoms, vein-wall injury, or cardiopulmonary limitation persists despite apparently appropriate treatment. The clinical success of DOACs therefore does not eliminate the need for new therapeutic strategies; instead, it sets a high bar for them. New agents must either be meaningfully safer, address thrombus resolution and long-term sequelae more directly, or fill gaps in populations inadequately served by present drugs. Unmet needs that drive new drug development The first and most obvious unmet need is bleeding. All currently available anticoagulants work by interfering with core components of physiological hemostasis. That shared mechanism explains why better efficacy is commonly purchased with more hemorrhage. This is seen not only with conventional anticoagulation but also when thrombolysis is added in intermediate-risk PE or when combination antithrombotic strategies are used in cardiovascular disease [31, 32]. The central scientific aspiration of the next generation of anticoagulants is therefore not simply to inhibit coagulation in a new way, but to inhibit thrombosis more selectively than hemostasis. The second unmet need is inadequate evidence in high-risk populations. Patients with severe chronic kidney disease, advanced cirrhosis, marked frailty, very old age, or complex cancer biology are common in VTE practice but were often excluded from pivotal DOAC trials [8, 33, 34]. This creates a recurrent clinical dilemma: the people at highest absolute thrombotic risk are frequently the same patients in whom clinicians are least comfortable extrapolating trial evidence. Any new platform that avoids renal clearance, causes less mucosal bleeding, or allows more stable exposure with fewer interactions would therefore have immediate clinical value even if it were only similarly effective to DOACs in the average patient. A third unmet need concerns thrombus biology itself. Standard anticoagulants do not actively dissolve established clot. They prevent extension and embolization while endogenous fibrinolysis works slowly and variably in the background. Recurrence after cessation of therapy remains common in unprovoked disease [3], and residual venous obstruction or vein-wall damage may persist despite technically successful anticoagulation [9, 10]. That limitation is particularly important when the therapeutic objective extends beyond acute survival or early recurrence to include preservation of valve function, prevention of PTS, and better long-term recovery after PE. These unmet needs are cumulative rather than isolated. A patient with cancer, advanced age, or chronic kidney disease often faces all three problems simultaneously: higher baseline thrombotic risk, narrower bleeding tolerance, and a greater likelihood of persistent disability after the event. This is one reason why the development of new VTE therapies has diversified. Some programs seek to improve anticoagulation itself; others seek to change recovery from established thrombosis. A coherent review must therefore ask not simply whether a strategy is “novel,” but what specific deficiency of current care it is designed to solve. These problems also clarify why emerging strategies should not be discussed as though they were all aimed at the same endpoint. A postoperative thromboprophylaxis trial that reduces mostly asymptomatic venographic DVT demonstrates proof of antithrombotic principle, but it does not establish efficacy for acute treatment of symptomatic DVT or PE. Conversely, an adjunctive fibrinolysis enhancer that improves clot-resolution biomarkers is not a substitute for anticoagulation unless it also prevents extension and recurrence. A more coherent VTE narrative therefore requires explicit alignment between mechanism, intended clinical setting, and the end points used to judge success. This framework guides the remainder of the review. Factor XI and XII inhibition: uncoupling thrombosis from hemostasis Biological rationale and pharmacological approaches Interest in FXI as a therapeutic target stems from a striking biological asymmetry. Congenital factor XII deficiency does not cause a bleeding phenotype, and factor XI deficiency is generally associated with only mild or procedure-related bleeding, particularly in tissues with high fibrinolytic activity [35, 36]. At the same time, epidemiologic and experimental evidence links higher FXI activity with thrombotic disease, whereas severe FXI deficiency is associated with lower rates of venous and arterial thromboembolism [37]. These observations suggested that the intrinsic pathway, particularly FXI amplification, might contribute more to pathologic thrombus propagation than to everyday hemostasis. Mechanistically, FXI can be activated by thrombin and thereby reinforce thrombin generation in a positive-feedback loop, a process that appears particularly relevant in settings of stasis, low tissue-factor exposure, or surface-mediated contact activation [38, 39]. FXII sits even further upstream and is of limited importance in normal hemostasis but highly relevant to artificial surfaces and device-associated coagulation. This has made the contact pathway especially attractive for extracorporeal circuits, dialysis, and other thrombosis contexts in which surface activation is prominent [40–42]. The broader appeal of this biology is intuitive: if thrombosis can be interrupted at a step that is relatively dispensable for physiological hemostasis, the therapeutic window may widen. Several pharmacological formats have been developed. Oral small-molecule FXIa inhibitors such as milvexian and asundexian act analogously to DOACs in that they provide rapid oral inhibition with relatively short half-lives and simple ambulatory dosing [43, 44]. Monoclonal antibodies, exemplified by abelacimab and osocimab, offer long-acting parenteral inhibition and are appealing where stable exposure or reduced renal dependence is desirable [45, 46]. Antisense oligonucleotides such as IONIS-FXIRx and fesomersen reduce hepatic synthesis of FXI and can sustain suppression for weeks, albeit with slower onset and the need for loading schedules [47–49]. A distinct contact-pathway-selective approach is represented by gruticibart (AB023), an antibody that binds FXI and blocks its activation by FXIIa while preserving thrombin-mediated FXI activation, thereby preferentially targeting surface-triggered coagulation [42, 50]. From a clinical standpoint, these differences matter. Small molecules are attractive when oral administration and rapid peri-procedural titration are priorities. Long-acting antibodies and antisense agents may be more useful when adherence, advanced kidney disease, or stable long-term exposure are dominant considerations. However, none of these formats can be judged solely by laboratory potency. What matters clinically is whether they can prevent symptomatic thrombosis at least as well as established therapy while maintaining the bleeding-sparing profile that originally motivated their development. Direct inhibition of FXII itself remains less advanced than FXI inhibition for VTE, but the target remains conceptually important. FXII appears particularly relevant when coagulation is initiated by artificial surfaces, polyphosphates, or other contact-activation triggers rather than by tissue-factor exposure from injured tissue. For that reason, the most persuasive near-term opportunities for FXII-directed or FXII-selective strategies may lie in extracorporeal medicine rather than in routine ambulatory treatment of spontaneous VTE [40–42]. This distinction again underscores the value of matching mechanism to thrombosis phenotype rather than expecting one pathway to solve every clinical scenario Table 1. Clinical evidence and current boundaries of inference The strongest evidence for FXI-directed therapy currently comes from postoperative thromboprophylaxis after total knee arthroplasty, a deliberately high-signal model of venous thrombosis. In the phase 2 FXI antisense trial by Büller and colleagues, the primary VTE outcome occurred in 27% of patients receiving 200 mg of FXI-ASO, 4% of those receiving 300 mg, and 30% of those receiving enoxaparin; bleeding occurred in 3%, 3%, and 8%, respectively [51]. In ANT-005, postoperative abelacimab reduced VTE to 13%, 5%, and 4% with 30-, 75-, and 150-mg doses versus 22% with enoxaparin, while major or clinically relevant nonmajor bleeding occurred in 2%, 2%, 0%, and 0%, respectively [45]. In AXIOMATIC-TKR, oral milvexian reduced postoperative VTE in a dose-dependent fashion; at total daily doses of at least 100 mg, event rates were lower than with enoxaparin, and major or clinically relevant nonmajor bleeding remained uncommon (approximately 1% with milvexian versus 2% with enoxaparin) [52]. Osocimab likewise established proof of concept: in FOXTROT, postoperative osocimab met prespecified criteria for noninferiority versus enoxaparin, the preoperative 1.8-mg/kg dose was superior, and major or clinically relevant nonmajor bleeding remained within the same general range as standard prophylaxis [53]. Across these orthopedic studies, the overall pattern is remarkably consistent: strong suppression of venographic VTE with little or no signal for increased clinically relevant bleeding [54]. That consistency is one reason the FXI field has generated unusually high enthusiasm relative to other anticoagulant platforms. Even so, interpretation should remain disciplined. These trials were optimized for mechanistic sensitivity, not for the messy heterogeneity of real-world acute VTE. Patients were highly selected, treatment duration was short, and the clinical stakes of a venographically detected distal DVT are not the same as those of recurrent symptomatic PE or fatal bleeding during months of treatment. These postoperative studies are important, but their meaning must be kept in context. They show that FXI inhibition can prevent postoperative venous thrombosis with little apparent bleeding penalty, thereby supporting the hypothesis that thrombosis and hemostasis can be separated to some extent. At the same time, most events in these trials were asymptomatic distal DVTs detected by mandated venography. This design is appropriate for proof-of-principle thromboprophylaxis, but it is not equivalent to demonstrating efficacy in acute symptomatic DVT, PE, or long-term secondary prevention. For that reason, the knee-arthroplasty data should be interpreted as foundational, not definitive, evidence for broader clinical replacement of DOACs or LMWH. The evidence base for acute VTE treatment is still developing. The most clinically advanced treatment programs have focused on cancer-associated thrombosis, where the need for less-bleeding-prone anticoagulation is particularly acute. Abelacimab is being evaluated in the phase 3 ASTER and MAGNOLIA programs for treatment of CAT, comparisons that should be far more informative for practice than orthopedic prophylaxis trials because they test recurrent symptomatic VTE and clinically relevant bleeding in a population where current options remain imperfect [55]. Until such data mature, however, it would be premature to assume that the efficacy observed in postoperative prophylaxis will translate directly into treatment of established acute VTE. Practical pharmacology will also shape how this class is ultimately used. Monthly antibodies may be attractive in oncology or in patients with adherence challenges, but long duration of effect raises questions about management around bleeding, urgent procedures, and unexpected need for invasive intervention. Oral FXIa inhibitors offer more familiar titration and interruption patterns, but their dependence on daily adherence and on renal or hepatic handling may reduce some of the theoretical advantage over DOACs. Antisense approaches may be especially appealing for chronic settings in which slow onset is acceptable, yet that same feature limits their suitability for immediate treatment of acute symptomatic VTE [44, 48, 49]. The atrial fibrillation experience also cautions against overgeneralization across thrombotic diseases. In PACIFIC-AF, asundexian showed a favorable bleeding profile relative to apixaban, but in the subsequent phase 3 OCEANIC-AF trial, efficacy proved inadequate for stroke prevention [56, 57]. This does not invalidate FXI inhibition in VTE; rather, it highlights that the biological contribution of FXI varies by disease context. Venous thrombosis, surface-induced thrombosis, and cardioembolic stroke should not be assumed to respond identically to the same degree or mode of FXI suppression. This is one reason VTE-specific treatment trials remain indispensable. A particularly informative body of evidence has emerged in extracorporeal and device-associated settings, where contact activation is dominant. In patients receiving hemodialysis, IONIS-FXIRx and its successor fesomersen reduced clotting in dialysis circuits without an obvious bleeding signal [49, 58]. In a placebo-controlled phase 2 trial, gruticibart (AB023), a contact-pathway-selective anti-FXI antibody, reduced dialyzer clotting during heparin-free dialysis [42]. Osocimab extended this experience in a larger randomized dialysis study: clinically relevant bleeding occurred in 6.9% and 4.9% of lower- and higher-dose osocimab recipients versus 7.8% with placebo, while major bleeding occurred in 1.3%, 0.9%, and 3.0%, respectively; dialysis-circuit clotting was numerically lower with osocimab [59]. In ambulatory cancer patients undergoing central-line placement, gruticibart was associated with catheter-associated thrombosis in 12.5% of the intervention cohort versus 40.0% in the companion control cohort, without clinically relevant bleeding [50]. Together, these studies strengthen the biological case for contact-pathway inhibition when thrombosis is surface-mediated rather than driven primarily by tissue-factor exposure. Additional information from extracorporeal circuits outside hemodialysis is still limited. Experimental work in cardiopulmonary bypass and simulated contact-activation models suggests that selective interference with FXI/FXII biology can reduce thrombin generation and circuit clotting with little impairment of hemostasis [41], but robust clinical data in ECMO, ventricular assist devices, or broader critical-care support remain sparse. Thus, beyond hemodialysis and catheter-associated thrombosis, FXI- or contact-pathway inhibition should still be considered hypothesis-generating rather than clinically established in extracorporeal medicine. Taken together, FXI inhibition is the most mature of the emerging antithrombotic platforms discussed in this review. However, its maturity is setting-specific. It is already supported by strong proof-of-principle data in postoperative thromboprophylaxis and by increasingly persuasive evidence in contact-activation–dominant scenarios such as dialysis and central venous devices. What remains unsettled is the central question for VTE practice: whether these agents can match or surpass existing anticoagulants for treatment of symptomatic acute DVT or PE and for secondary prevention of recurrent VTE while preserving the bleeding advantage that makes the class attractive in the first place [54, 55, 60]. Enhancing fibrinolysis: targeting endogenous clot resolution Biological rationale Anticoagulants prevent further fibrin formation, but they do not directly accelerate the removal of fibrin that is already present. This therapeutic limitation is especially relevant in VTE because residual clot burden, delayed recanalization, and ongoing vein-wall injury all contribute to recurrent events and chronic disability [9, 10]. The most direct pharmacological way to eliminate clot has historically been thrombolysis with exogenous plasminogen activators such as alteplase. Although thrombolysis is lifesaving in selected patients with hemodynamically unstable PE and can improve early patency in some severe DVT cases, bleeding risk—including intracranial and fatal hemorrhage—has prevented routine use in most patients [61–65]. The limitations of conventional thrombolysis are instructive for the newer fibrinolytic approaches. Trials of systemic and catheter-directed thrombolysis have repeatedly shown that faster early clot clearance does not automatically translate into large reductions in PTS or durable functional benefit, especially when bleeding forces dose limitation or narrow patient selection [64, 65]. Any new fibrinolysis-enhancing therapy must therefore solve a dual problem: it must be safer than thrombolysis and it must link enhanced clot dissolution to outcomes that matter clinically, not merely to laboratory lysis times or short-term imaging changes. An appealing alternative is to increase the efficiency of endogenous fibrinolysis rather than to flood the circulation with an exogenous thrombolytic. Three physiological inhibitors are particularly relevant. α2-Antiplasmin (α2AP) neutralizes plasmin and protects fibrin from lysis. PAI-1 suppresses tissue plasminogen activator and urokinase, thereby limiting plasmin generation. TAFI removes C-terminal lysines from fibrin, making the clot a poorer template for plasminogen activation and plasmin amplification. Elevated activity of these systems is associated with hypofibrinolysis and with thrombotic risk, at least in selected populations [66–70]. This biology is attractive because the therapeutic goal differs from that of anticoagulation. An anticoagulant is judged mainly by prevention of extension and recurrence. A fibrinolysis-enhancing therapy is judged by whether it can reduce clot burden faster, improve perfusion or vein patency, limit right-ventricular strain in PE, or ultimately reduce late disability such as PTS or chronic thromboembolic disease. The intended role of these drugs is therefore usually adjunctive rather than substitutive: they are meant to be added to standard anticoagulation, not to replace it Table 2. Preclinical data support the concept. Experimental inhibition or deficiency of α2AP, PAI-1, or TAFI accelerates clot resolution in animal models, and humans with inherited deficiency of some fibrinolytic inhibitors do not display the kind of catastrophic spontaneous bleeding that would make the strategy untenable [68, 71–73]. Nonetheless, the translational challenge is substantial. Enhancing fibrinolysis enough to change meaningful clinical outcomes without recreating the bleeding liabilities of thrombolysis is a narrow and demanding therapeutic target. Table 2. Current clinical programs and their limitations Among fibrinolysis-enhancing approaches, α2-antiplasmin inhibition is currently the most clinically developed. TS23, a monoclonal antibody targeting α2AP, completed early-phase safety evaluation and is being studied in intermediate-risk PE in the NAIL-IT program [73, 74]. A second α2AP-directed antibody, BAY3018250, has entered phase 2 testing in symptomatic proximal DVT in the SIRIUS study [73, 74]. This distinction is important because α2AP inhibition is intended to facilitate endogenous clot lysis after standard anticoagulation has stabilized the thrombotic process. In other words, these agents are being developed as clot-resolution adjuncts, not as primary anticoagulants. The current α2AP programs are conceptually attractive for several reasons. First, they address a therapeutic gap that anticoagulants do not: the slow and often incomplete removal of pre-existing clot. Second, they are being tested in clinically relevant syndromes—intermediate-risk PE and proximal DVT—where faster resolution could plausibly improve symptoms or reduce late sequelae. Third, they provide a more disciplined framework than older thrombolytic strategies because success will depend on demonstrating meaningful benefit without a hemorrhagic penalty. At present, however, their evidence base remains early phase. Published human data are still insufficient to establish benefit on hard outcomes such as recurrent VTE, PTS, or long-term cardiopulmonary recovery. The three major fibrinolytic targets also differ in how directly they influence clot breakdown. α2AP inhibition prolongs plasmin activity once plasmin has been generated, making it a relatively direct amplifier of fibrin degradation. PAI-1 inhibition acts further upstream by freeing endogenous plasminogen activators, which may make efficacy more dependent on the patient’s baseline fibrinolytic capacity and inflammatory milieu. TAFI inhibition works through the structure of the fibrin surface and may therefore produce subtler, context-dependent effects. These mechanistic differences likely help explain why α2AP programs have moved more decisively into clinical VTE studies, whereas TAFI programs have often shown pharmacodynamic activity without a clearly transformative clinical signal [70–77]. PAI-1 remains a biologically compelling but clinically less mature target. Elevated PAI-1 levels are associated with future VTE risk, and the molecule has a plausible mechanistic role in the hypofibrinolytic phenotype observed in inflammatory, metabolic, and malignant states [66, 69]. However, compared with α2AP inhibition, the clinical development of PAI-1–directed therapy in VTE remains earlier and less defined. This makes PAI-1 an attractive target for future translational work, but not yet one that can be discussed alongside FXI inhibition or α2AP inhibition as a clinically mature strategy. TAFI inhibition illustrates both the promise and frustration of fibrinolysis-directed drug development. Several programs—including UK-396,082, AZD-9684, DS-1040, and S62798—advanced into early clinical testing [70, 74–78]. The results were mixed. Some agents improved fibrinolysis biomarkers or imaging parameters without excess bleeding, suggesting that the mechanism was pharmacologically active. Yet clear incremental clinical efficacy proved difficult to show. DS-1040, for example, accelerated laboratory clot-lysis measures but failed to improve key outcomes in acute PE when added to anticoagulation [76]. Other programs were stopped despite seemingly acceptable safety, reflecting either strategic reprioritization or the difficulty of proving enough clinical benefit to justify further development. Safety interpretation in this field also requires nuance. The absence of large bleeding signals in early studies is encouraging, but early-phase adjunctive trials are usually small, heavily selected, and not powered to detect infrequent major hemorrhage. Moreover, the safety question is not simply whether bleeding occurs more often, but whether bleeding occurs in patients who are already anticoagulated and potentially have large clot burden, right-ventricular strain, cancer, or organ dysfunction. For fibrinolysis-enhancing therapy, the eventual standard will likely be a clinically meaningful reduction in residual thrombus or disability with no material increase in major or clinically relevant nonmajor bleeding over and above background anticoagulation. These results are informative rather than discouraging. They suggest that the fibrinolytic system can indeed be modulated pharmacologically without automatically causing major bleeding, but they also indicate that biomarker improvement is not enough. Future trials will likely need tighter patient selection, better linkage between mechanism and phenotype, and end points that capture why clot resolution matters clinically—for example, residual venous obstruction, right-ventricular recovery, PTS severity, exercise limitation, or chronic thromboembolic complications [73, 79, 80]. At present, fibrinolysis-enhancing therapy should therefore be viewed as an exploratory adjunctive strategy. Its greatest potential may lie in patients with large clot burden, delayed recanalization, or particularly high risk of chronic sequelae, rather than in unselected VTE populations. In contrast to FXI inhibition, which aims primarily to improve the safety of anticoagulation, fibrinolysis-enhancing programs aim to change the biology of recovery after the clot has already formed. That distinction is central to interpreting both their promise and their current limitations. This has implications for future study design. The best candidates for fibrinolysis-enhancing therapy may not be all-comers with VTE, but patients with phenotypes suggesting inadequate endogenous clot resolution—for example, extensive proximal DVT, residual thrombus after an initial treatment window, or PE accompanied by substantial but not immediately unstable right-ventricular strain. Enriching trials for these phenotypes may be more informative than repeating broad, unselected adjunctive studies in which only a minority of patients stand to gain from accelerated thrombus resolution. Clinical synthesis: relative maturity and likely roles of emerging therapies When the emerging VTE pipeline is viewed hierarchically, the relative maturity of different strategies becomes clearer. FXI-directed anticoagulation is the most advanced. It has reproducible randomized data in postoperative thromboprophylaxis, a biologically coherent role in contact-activation settings, and active treatment programs in clinically important populations such as CAT [45, 50–52, 55, 59]. Fibrinolysis-enhancing therapy occupies the next tier: the biology is strong and early human testing is under way, but efficacy data remain preliminary and adjunctive rather than substitutional. Thrombo-inflammatory strategies come after that. Their mechanistic rationale is persuasive, especially for vein-wall injury and PTS, but clinical efficacy data are sparse and fragmented. This hierarchy also aligns with distinct clinical use-cases. A bleeding-sparing anticoagulant is most relevant to initial treatment and secondary prevention, particularly in patients who need months of therapy or who face a narrow efficacy-safety balance. A fibrinolysis enhancer is most relevant to acute clot burden and long-term tissue recovery. A thrombo-inflammatory adjunct is most relevant to vein-wall preservation, inflammatory amplification, and possibly prevention of chronic complications. Conflating these purposes makes the literature appear more mature than it is, because success in one domain does not automatically imply success in another. The most plausible future clinical pathway is therefore not that one new class will replace all existing therapy, but that different mechanisms will be matched to different problems. If phase 3 treatment trials are positive, FXI inhibition could become a preferred anticoagulant platform for patients at high bleeding risk, for selected cancer patients, or for those with advanced kidney disease. If α2AP-directed therapy proves effective, it may become an adjunct in patients with proximal DVT or intermediate-risk PE in whom faster clot resolution is likely to matter. If selectin or PSGL-1 modulation succeeds, its value may lie less in preventing acute recurrence than in limiting thrombo-inflammatory injury and chronic venous remodeling. Endpoint selection deserves special emphasis. In prophylaxis trials, asymptomatic distal DVT detected by mandatory imaging may be acceptable because it maximizes event capture and statistical efficiency. In treatment trials, however, clinicians care primarily about recurrent symptomatic DVT or PE, fatal PE, net clinical benefit, and bleeding severe enough to alter management. For adjunctive thrombus-resolution strategies, imaging or biomarker end points may be mechanistically useful early on, but regulatory and practice-changing relevance will likely require demonstration of better patient function, less residual obstruction, less right-ventricular dysfunction, or lower rates of PTS. The “right” end point is therefore inseparable from the intended role of the drug being tested. Several translational issues will determine whether these strategies move from attractive science to routine care. These include availability of reversal approaches, peri-procedural management, route and frequency of dosing, interaction potential, cost, and the feasibility of identifying the patients most likely to benefit. Equally important is trial design. Future studies must distinguish prophylaxis from treatment, symptomatic from asymptomatic events, and acute efficacy from prevention of late disability. Without that discipline, promising biology risks being oversold before the relevant clinical question has actually been answered. Implementation may ultimately be as important as efficacy. Some patients will value an oral daily drug, whereas others may prefer infrequent injections if this reduces treatment burden. Health systems will weigh drug acquisition costs against avoidance of bleeding admissions, monitoring burden, or long-term disability. Regulators and guideline panels will also expect clear evidence that a new mechanism adds something clinically relevant beyond an already effective standard of care. In VTE, that evidentiary standard is appropriately high because DOACs work well for most patients; novel agents will succeed only if they solve specific problems that current therapy leaves unresolved. Thrombo-inflammatory and other adjunct strategies VTE is not solely a coagulation-cascade disorder. Experimental and translational work increasingly supports the concept of immunothrombosis, in which neutrophils, monocytes, endothelial activation, platelets, and neutrophil extracellular traps amplify clot formation and shape the subsequent inflammatory remodeling of the vein wall [81–84]. These pathways are particularly relevant to DVT, where thrombus resolution and chronic venous fibrosis are tightly linked. Standard anticoagulants suppress thrombin generation but do not directly address leukocyte recruitment, endothelial adhesion, or the inflammatory programs that may contribute to PTS. Selectins and their ligands are among the best-characterized mediators of this interface. P-selectin on platelets and endothelium and E-selectin on activated endothelium promote leukocyte tethering and activation, while PSGL-1 on leukocytes mediates these adhesive interactions [83, 85–88]. In animal models, blockade of P-selectin or E-selectin reduces thrombus formation, promotes thrombus resolution, and lessens vein-wall fibrosis, all without the bleeding liability expected from conventional anticoagulation [86, 89, 90]. This makes selectin biology attractive not only for acute thrombosis prevention but also for the longer-term objective of preserving venous function Table 3. Clinical development, however, remains early. SelK2, a monoclonal antibody targeting PSGL-1, was tested against enoxaparin in an orthopedic thromboprophylaxis study as a proof-of-concept effort to interrupt leukocyte-driven thrombosis in humans [91]. Uproleselan, an E-selectin antagonist, has a solid mechanistic rationale and favorable early safety data, but the pilot DVT study was terminated after minimal enrollment, leaving no usable efficacy signal [92]. Direct P-selectin blockade has compelling preclinical support and an existing clinical precedent in sickle cell disease, yet no direct VTE efficacy trials have matured [88, 93]. Biomarker studies support the concept even when clinical trial data are sparse. Elevated soluble P-selectin correlates with thrombotic risk in malignancy, and inflammatory contexts such as cancer or severe infection provide exactly the type of leukocyte-endothelial activation in which selectin-directed therapies might matter most [94–97]. However, biomarkers are best interpreted as biological plausibility, not as proof of therapeutic benefit. The gap between mechanistic association and clinical efficacy remains wide in this area Table 3. The clinical niche for thrombo-inflammatory modulation is therefore still hypothetical. These agents seem better suited as adjuncts than as standalone anticoagulants, because their main strength may be to attenuate leukocyte recruitment, endothelial activation, and vein-wall injury rather than to replace fibrin-targeted anticoagulation entirely. They may eventually prove useful in selected inflammatory phenotypes of VTE, in PTS prevention, or in cancer-associated thrombosis where thrombosis and inflammation are deeply intertwined [90, 94, 95]. But such possibilities remain exploratory and should not be presented as near-term clinical practice. This caution is particularly important when discussing oncology. Selectin biology also participates in tumor–microenvironment interactions, and preclinical or hematologic studies suggest that selectin blockade can influence cell adhesion, chemosensitivity, or marrow trafficking [88, 91, 92]. However, these observations do not establish a clinically meaningful antitumor effect in patients with VTE. At present, any oncology relevance of selectin inhibitors should be described as biologically interesting and potentially complementary, not as an established anticancer advantage. Overall, thrombo-inflammatory modulation remains an intellectually attractive but immature field. Its promise lies in expanding VTE therapy beyond clot prevention toward protection of the vein wall and the inflammatory microenvironment that surrounds thrombosis. Whether that promise translates into lower PTS rates, better symptom recovery, or less recurrence will depend on much more direct clinical testing than is presently available. Special considerations in high-risk populations Cancer-associated thrombosis (CAT) CAT remains one of the most difficult VTE settings because both thrombotic and bleeding risks are amplified. LMWH was the historical standard after evidence that it reduced recurrence better than warfarin in cancer patients [13]. DOACs subsequently improved convenience and, in many patients, efficacy, but the trade-off has been more bleeding in some tumor types—especially gastrointestinal and genitourinary malignancies—while apixaban has shown the most reassuring bleeding profile among the DOACs studied in CAT [7, 98–103]. Thus, contemporary practice is already more individualized in CAT than in the average VTE population, with tumor type, bleeding phenotype, drug interactions, thrombocytopenia, and procedures all influencing drug selection. Several day-to-day issues make CAT more difficult than non-cancer VTE. Patients often require biopsies, surgery, central venous access, or interruption of therapy around invasive procedures. They may become thrombocytopenic during chemotherapy, develop mucosal lesions, or receive agents that alter drug transport and metabolism. The value of a safer anticoagulant in CAT therefore goes beyond reducing spontaneous bleeding; it may also permit more consistent continuation of therapy across a volatile treatment course [103, 104]. This is precisely why FXI inhibition is so attractive in oncology. If the class can preserve efficacy while reducing bleeding, it could address one of the largest remaining unmet needs in CAT [55, 104, 105]. Early evidence is encouraging but still limited. In patients with cancer undergoing central-line placement, gruticibart was associated with catheter-associated thrombosis in 12.5% of the intervention cohort versus 40.0% in the companion control cohort, without clinically relevant bleeding [50]. Although this was a small study and focused on device-associated thrombosis rather than symptomatic CAT treatment, it supports the biological relevance of contact-pathway inhibition in cancer. The more practice-changing question is whether FXI inhibition can treat established CAT at least as effectively as current anticoagulants. That issue is being addressed in the ongoing abelacimab programs ASTER and MAGNOLIA [55]. If these studies confirm reduced bleeding without loss of efficacy, FXI inhibition could be particularly valuable in patients with gastrointestinal or genitourinary malignancies, in patients requiring repeated procedures, and in those with complex drug–drug interaction profiles. Until those data are available, however, FXI inhibitors should be regarded as promising rather than established alternatives in CAT. Other emerging approaches in CAT remain more speculative. Fibrinolysis-enhancing therapy could theoretically benefit patients with large clot burden or incomplete recanalization, but no dedicated CAT data exist. Likewise, thrombo-inflammatory strategies may be relevant because cancer-associated thrombosis involves cytokine activation, leukocyte–platelet interactions, and neutrophil extracellular traps [94, 95], yet direct clinical evidence is not available. For the near term, the most plausible next advance in CAT remains bleeding-sparing anticoagulation rather than inflammation- or fibrinolysis-directed therapy. For the present, the practical implication is selective optimism. Patients with CAT are among the most likely to benefit from safer anticoagulant platforms, but they are also among the least suitable for broad extrapolation from non-cancer thrombosis trials. Until phase 3 treatment data are available, the correct posture is to continue individualized standard care while recognizing that oncology is probably one of the settings in which FXI-based therapy could make the greatest clinical difference if efficacy is confirmed. Older adults Older adults experience both a high absolute incidence of VTE and a high burden of anticoagulant-related bleeding. DOACs are generally preferred over VKAs in this population because they reduce intracranial hemorrhage and simplify treatment, but careful dosing and attention to renal function, body weight, polypharmacy, and frailty remain essential [8, 106–113]. In practice, clinicians often de-intensify therapy or shorten treatment because the perceived bleeding risk is high, even when the thrombotic risk is also substantial. The appeal of emerging agents in older adults therefore lies mainly in safety and usability. Long-acting biologic FXI inhibitors are not dependent on renal clearance to the same extent as current oral anticoagulants and may ultimately offer a wider therapeutic window, which would be particularly valuable in very old patients with frailty, falls risk, or multiple comorbidities [114]. However, this remains a forward-looking possibility rather than an evidence-based recommendation. There are not yet dedicated VTE treatment data showing that FXI inhibition improves net clinical benefit specifically in frail older adults, and there are no comparable data for fibrinolysis-enhancing or selectin-directed strategies. For now, the practical message is that older age increases the need for safer therapies, but it does not yet justify extrapolating beyond the evidence base already available. Adherence and treatment burden also deserve attention in older adults. Warfarin monitoring can be logistically difficult, but oral twice-daily treatment may also be challenging in patients with cognitive impairment, polypharmacy, or limited caregiver support. Long-acting agents could theoretically improve persistence, but they also reduce flexibility if the clinical situation changes quickly. Thus, even if FXI-directed biologics ultimately prove safer, their optimal role in geriatric VTE care will depend on more than bleeding rates alone; practical issues of reversibility, follow-up, and caregiver infrastructure will matter as well. Accordingly, current care in older adults still rests on individualized use of the best-validated anticoagulants, optimization of modifiable bleeding risks, and thoughtful decisions about duration and dose intensity. Emerging therapies are highly relevant to this population, but they remain investigational until older, frailer, and multimorbid patients are specifically represented in definitive VTE trials. Renal impairment Advanced renal impairment is one of the clearest areas of unmet need in VTE therapy. Because all DOACs undergo renal elimination to varying degrees, severe chronic kidney disease and dialysis were major exclusions in the pivotal trials. UFH and VKAs therefore remain common default options, with all the familiar disadvantages of infusion requirements, monitoring burden, and variable anticoagulant control [11, 33, 115–118]. In selected centers, apixaban is used cautiously in advanced chronic kidney disease, but the evidence base remains less secure than in patients with preserved renal function. FXI- and contact-pathway inhibition are especially attractive here because several agents avoid meaningful renal clearance and because dialysis itself is a surface-mediated, contact-activation–dominant thrombotic environment. This has already produced a rare example of mechanistic alignment between disease biology and drug target. IONIS-FXIRx and fesomersen reduced dialysis-circuit clotting [49, 58], gruticibart reduced dialyzer clotting during heparin-free hemodialysis [42], and osocimab showed low clinically relevant bleeding with less circuit clotting than placebo in patients receiving chronic hemodialysis [59]. These findings do not yet prove efficacy for treatment of spontaneous DVT or PE in end-stage kidney disease, but they strongly suggest that FXI-directed therapy could be particularly valuable in this population if treatment trials are successful. Renal failure also highlights an underappreciated aspect of thrombosis care: vascular-access and device thrombosis. Many patients with end-stage kidney disease have repeated contact between blood and artificial surfaces, whether through dialysis circuits or catheters. This makes them a natural testing ground for contact-pathway–selective therapy and partly explains why the renal field has become a leading source of human proof-of-concept data for FXI inhibition [42, 58, 59, 118]. In that sense, renal medicine is not peripheral to VTE innovation; it has become one of the most informative experimental platforms for it. Importantly, evidence in renal impairment should again be separated by setting. Data from dialysis circuits support the biology of contact-pathway inhibition and provide a safety signal in patients who bleed easily. They do not automatically establish efficacy for acute symptomatic VTE treatment, where recurrent-event prevention is the key endpoint. Thus, patients with severe kidney disease represent one of the most compelling target populations for future FXI-based VTE treatment trials, but current management must still rely mainly on individualized use of established anticoagulants. In patients with CKD stages 3–4, careful dose adjustment and monitoring remain essential; in end-stage kidney disease, specialist input is often warranted until more definitive bleeding-sparing alternatives become available. Hepatic impairment Significant liver disease presents a different but equally complex problem. Cirrhosis produces a fragile “rebalanced” hemostatic state in which both bleeding and thrombosis can occur. Baseline INR prolongation does not reliably indicate protection from thrombosis, yet portal vein thrombosis and systemic VTE remain clinically relevant in cirrhosis [34, 119–121]. In mild hepatic dysfunction, some DOACs—especially apixaban—can be used cautiously, but evidence becomes sparse in more advanced disease and severe cirrhosis was excluded from the major VTE trials [34, 121–128]. LMWH therefore remains an important option in many patients, while any anticoagulation decision must be individualized to bleeding phenotype, variceal risk, platelet count, and transplant considerations. Current drugs are all imperfect in this setting. Warfarin is difficult to interpret when baseline INR is abnormal, and fluctuations in nutrition, hepatic synthetic function, and intercurrent illness can further destabilize anticoagulation. LMWH avoids INR confusion but requires injections and may accumulate in some patients with combined hepatorenal dysfunction. DOACs offer practical advantages in selected Child-Pugh A or B patients, yet confidence falls sharply as liver disease advances [34, 119–128]. These shortcomings explain why hepatic impairment remains one of the most important but least studied indications for safer and more predictable anticoagulants. At first glance, biologic FXI inhibitors appear attractive because they do not depend heavily on hepatic metabolism in the same way as some oral anticoagulants. However, extrapolation is not straightforward. Cirrhosis alters both procoagulant and anticoagulant pathways, and factor XI levels themselves may be reduced in advanced liver disease [125]. Thus, the theoretical benefits of FXI inhibition in cirrhosis must be balanced against the possibility that the target is already biologically diminished and that the hemostatic consequences of further suppression may not mirror those seen in patients without liver disease. This complexity is especially relevant in portal vein thrombosis. For example, in patients with small, nonocclusive portal vein thrombosis and large untreated varices, many centers first optimize variceal prophylaxis and endoscopic management and then reassess whether anticoagulation can be started safely [121, 127]. This sequence reflects the fact that anticoagulation decisions in cirrhosis are often driven less by the name of the drug than by the broader portal-hypertension phenotype and bleeding terrain. Emerging therapies may eventually expand options in hepatic impairment, but at present the evidence is too limited to recommend them outside research settings. The most responsible conclusion is therefore a restrained one: liver disease is a population in which safer, more predictable anticoagulants are badly needed, but it is also a population in which mechanistic extrapolation is particularly hazardous. Dedicated trials, rather than optimism based on pharmacokinetic convenience alone, will be required before novel agents can be integrated into routine care. Conclusions VTE management has advanced substantially with DOACs, but current therapy still leaves three important problems unresolved: bleeding, uncertainty in special populations, and incomplete thrombus resolution with persistent long-term disability. These limitations justify a broader therapeutic strategy than anticoagulation alone. The emerging pipeline now includes agents designed to reduce bleeding liability by targeting FXI or selected contact-pathway mechanisms, agents designed to accelerate endogenous fibrinolysis and possibly improve recovery after clot formation, and adjunctive approaches designed to attenuate thrombo-inflammatory injury to the vein wall. Among these strategies, FXI inhibition is clearly the most mature. The existing randomized evidence strongly supports the concept of hemostasis-sparing anticoagulation in postoperative prophylaxis and in contact-activation settings such as hemodialysis and device-associated thrombosis. However, the decisive question for VTE practice—whether these agents can replace or outperform current anticoagulants for treatment of symptomatic DVT or PE and for long-term secondary prevention—still depends on ongoing treatment trials. Fibrinolysis-enhancing therapies and thrombo-inflammatory modulators remain promising but earlier-stage programs whose value is likely to be adjunctive and mechanism-specific rather than universal. This is especially true in special populations. Cancer, advanced kidney disease, severe frailty, and cirrhosis are not marginal subgroups; they are the settings in which the limitations of current therapy become most visible and in which the potential value of mechanism-specific innovation is greatest. At the same time, they are precisely the settings in which premature extrapolation is most hazardous. The field therefore needs not only new drugs, but also better inclusion of these populations in the trials that will define their future role. The next phase of progress will depend on disciplined clinical translation. Future studies must match mechanism to clinical problem, distinguish prophylaxis from treatment, and prioritize patient-centered outcomes such as recurrent symptomatic VTE, major or clinically relevant nonmajor bleeding, functional recovery, and prevention of PTS or chronic thromboembolic complications. If these hurdles are met, VTE care may evolve from a model centered exclusively on anticoagulation toward one based on mechanism-specific, patient-tailored regimens that improve both safety and long-term outcomes. Until then, the most prudent view is one of guarded optimism: the science is compelling, but the evidence remains uneven and highly dependent on setting. Table 1An overview of key factor XI inhibitors and their development status in VTE-related indicationsAgent (Type)Development Stage & IndicationsKey Findings / StatusAbelacimab(monoclonal antibody)Phase 2 completed – VTE prophylaxis after total knee arthroplasty (ANT-005 TKA trial). Phase 3 ongoing – VTE treatment in cancer (ASTER & MAGNOLIA trials).Single IV dose post-operatively reduced DVT incidence vs. enoxaparin (4% vs. 21% in ANT-005) with 90% lower bleeding. Currently being tested against apixaban and dalteparin in cancer-associated thrombosis.Osocimab(monoclonal antibody)Phase 2 completed – VTE prophylaxis post knee arthroplasty (FOXTROT trial).Single dose of osocimab was non-inferior to enoxaparin for postoperative DVT prevention. Achieved factor XI suppression with no excess bleeding; further development ongoing for medical prophylaxis.Milvexian(small-molecule FXIa inhibitor)Phase 2 completed – VTE prophylaxis post knee arthroplasty (AXIOMATIC-TKR study).Oral milvexian dose-dependently reduced DVT rates; the highest dose cut asymptomatic DVT from ~ 30% (enoxaparin) to ~ 12%. Bleeding rates were low and similar to enoxaparin. Now entering phase 3 (OCEANIC program) for stroke prevention and other indications.Asundexian(small-molecule FXIa inhibitor)Phase 2 (PACIFIC) in atrial fibrillation and coronary disease; Phase 3 trial in AF (OCEANIC-AF) terminated early. Not yet tested in VTE treatment or prophylaxis trials.Showed effective FXIa inhibition and no major bleeding in phase 2. However, in a Phase 3 AF trial comparing asundexian 50 mg to apixaban, asundexian was associated with higher stroke rates, leading to trial stoppage. This raised questions about whether the dose or approach was insufficient for high-risk arterial thrombosis. Further studies in VTE are awaited.IONIS-FXIRx(antisense oligonucleotide)Phase 2 completed – VTE prophylaxis post knee replacement. Phase 2 in ESRD on hemodialysis completed.In a placebo-controlled trial in orthopedic surgery, FXI-ASO cut post-op DVT risk by ~ 70% vs. enoxaparin (4% vs. 30% DVT) with no increase in bleeding. In ESRD patients, monthly injections of FXI-ASO allowed heparin-free dialysis with reduced clotting in circuits and no bleeding. Development of a second-generation ASO (fesomersen) is in progress.Selected factor XI inhibitors in clinical development for VTE prevention and treatment. These novel agents employ various mechanisms (monoclonal antibody, small-molecule inhibitor, antisense oligonucleotide) to suppress factor XI activity. Key trial results and statuses are summarized. Enoxaparin was the common control in orthopedic prophylaxis trials. FXI = factor XI; FXIa = activated factor XI; DVT = deep vein thrombosis; VTE = venous thromboembolism; AF = atrial fibrillation Table 1An overview of key factor XI inhibitors and their development status in VTE-related indicationsAgent (Type)Development Stage & IndicationsKey Findings / StatusAbelacimab(monoclonal antibody)Phase 2 completed – VTE prophylaxis after total knee arthroplasty (ANT-005 TKA trial). Phase 3 ongoing – VTE treatment in cancer (ASTER & MAGNOLIA trials).Single IV dose post-operatively reduced DVT incidence vs. enoxaparin (4% vs. 21% in ANT-005) with 90% lower bleeding. Currently being tested against apixaban and dalteparin in cancer-associated thrombosis.Osocimab(monoclonal antibody)Phase 2 completed – VTE prophylaxis post knee arthroplasty (FOXTROT trial).Single dose of osocimab was non-inferior to enoxaparin for postoperative DVT prevention. Achieved factor XI suppression with no excess bleeding; further development ongoing for medical prophylaxis.Milvexian(small-molecule FXIa inhibitor)Phase 2 completed – VTE prophylaxis post knee arthroplasty (AXIOMATIC-TKR study).Oral milvexian dose-dependently reduced DVT rates; the highest dose cut asymptomatic DVT from ~ 30% (enoxaparin) to ~ 12%. Bleeding rates were low and similar to enoxaparin. Now entering phase 3 (OCEANIC program) for stroke prevention and other indications.Asundexian(small-molecule FXIa inhibitor)Phase 2 (PACIFIC) in atrial fibrillation and coronary disease; Phase 3 trial in AF (OCEANIC-AF) terminated early. Not yet tested in VTE treatment or prophylaxis trials.Showed effective FXIa inhibition and no major bleeding in phase 2. However, in a Phase 3 AF trial comparing asundexian 50 mg to apixaban, asundexian was associated with higher stroke rates, leading to trial stoppage. This raised questions about whether the dose or approach was insufficient for high-risk arterial thrombosis. Further studies in VTE are awaited.IONIS-FXIRx(antisense oligonucleotide)Phase 2 completed – VTE prophylaxis post knee replacement. Phase 2 in ESRD on hemodialysis completed.In a placebo-controlled trial in orthopedic surgery, FXI-ASO cut post-op DVT risk by ~ 70% vs. enoxaparin (4% vs. 30% DVT) with no increase in bleeding. In ESRD patients, monthly injections of FXI-ASO allowed heparin-free dialysis with reduced clotting in circuits and no bleeding. Development of a second-generation ASO (fesomersen) is in progress.Selected factor XI inhibitors in clinical development for VTE prevention and treatment. These novel agents employ various mechanisms (monoclonal antibody, small-molecule inhibitor, antisense oligonucleotide) to suppress factor XI activity. Key trial results and statuses are summarized. Enoxaparin was the common control in orthopedic prophylaxis trials. FXI = factor XI; FXIa = activated factor XI; DVT = deep vein thrombosis; VTE = venous thromboembolism; AF = atrial fibrillation An overview of key factor XI inhibitors and their development status in VTE-related indications Abelacimab (monoclonal antibody) Osocimab (monoclonal antibody) Milvexian (small-molecule FXIa inhibitor) Asundexian (small-molecule FXIa inhibitor) IONIS-FXIRx (antisense oligonucleotide) Selected factor XI inhibitors in clinical development for VTE prevention and treatment. These novel agents employ various mechanisms (monoclonal antibody, small-molecule inhibitor, antisense oligonucleotide) to suppress factor XI activity. Key trial results and statuses are summarized. Enoxaparin was the common control in orthopedic prophylaxis trials. FXI = factor XI; FXIa = activated factor XI; DVT = deep vein thrombosis; VTE = venous thromboembolism; AF = atrial fibrillation Table 2Main fibrinolysis regulators and the current status of inhibitorsTarget (Function)Therapeutic StrategyDevelopment Status / Key Resultsα2-Antiplasmin (plasmin inhibitor)Monoclonal antibodies (e.g. TS23) neutralizing α2AP.Phase 1: TS23 in healthy volunteers – well tolerated, achieved α2AP inhibition (complete plasmin activity in plasma); no bleeding signals. Phase 2: NAIL-IT trial (n = 32) testing IV TS23 at three doses vs. placebo in acute intermediate-high-risk PE (with standard heparin) is ongoing. Expected to report on improved clot lysis (via imaging) and safety.PAI-1 (tPA/urokinase inhibitor)Small-molecule inhibitor of PAI-1 (e.g. BAY 3018250). Also exploring antibodies and stapled peptides.Phase 1: Prior compounds had limited success; no major clinical data published. Phase 2: SIRIUS trial (n ≈ 255) evaluating oral BAY 3,018,250 vs. placebo in acute proximal DVT (with standard anticoagulation) is in progress. Primary endpoints: clot burden reduction by ultrasound and composite bleeding outcomes. No results yet; if positive, will prove first clinical benefit of PAI-1 inhibition in VTE.TAFI (fibrinolysis inhibitor via fibrin remodeling)Small-molecule inhibitors (e.g. AZD-9684, DS-1040, UK-396,082, S62798). Monoclonal antibodies and nanobodies also created.Phase 2 trials: AZD-9684 – in 58 PE patients, improved lung perfusion and fibrinolysis markers with no bleeding, but development halted. DS-1040 – in 125 submassive PE patients, did not improve outcomes vs. placebo (no added benefit on clot lysis or RV function); development stopped. S62798 – Phase 1 in 56 healthy subjects showed good tolerability, but Phase 2 in PE was discontinued pre-enrollment. UK-396,082 – Phase 1 done, program ended. Overall, TAFI inhibitors accelerate fibrinolysis in lab and animal models, but translating to clinical benefit has been challenging; no active late-stage trials currently.Inhibitors of key fibrinolytic regulators under investigation. By blocking α2-antiplasmin or PAI-1, endogenous fibrinolytic activity (plasmin/tPA) may be enhanced, potentially improving clot resolution in VTE. TAFI inhibitors have also been tested, but none have progressed to Phase 3. The table summarizes representative agents and trial outcomes. As of 2025, α2AP and PAI-1 inhibitors show promise in early trials, whereas TAFI inhibitor development has encountered setbacks Table 2Main fibrinolysis regulators and the current status of inhibitorsTarget (Function)Therapeutic StrategyDevelopment Status / Key Resultsα2-Antiplasmin (plasmin inhibitor)Monoclonal antibodies (e.g. TS23) neutralizing α2AP.Phase 1: TS23 in healthy volunteers – well tolerated, achieved α2AP inhibition (complete plasmin activity in plasma); no bleeding signals. Phase 2: NAIL-IT trial (n = 32) testing IV TS23 at three doses vs. placebo in acute intermediate-high-risk PE (with standard heparin) is ongoing. Expected to report on improved clot lysis (via imaging) and safety.PAI-1 (tPA/urokinase inhibitor)Small-molecule inhibitor of PAI-1 (e.g. BAY 3018250). Also exploring antibodies and stapled peptides.Phase 1: Prior compounds had limited success; no major clinical data published. Phase 2: SIRIUS trial (n ≈ 255) evaluating oral BAY 3,018,250 vs. placebo in acute proximal DVT (with standard anticoagulation) is in progress. Primary endpoints: clot burden reduction by ultrasound and composite bleeding outcomes. No results yet; if positive, will prove first clinical benefit of PAI-1 inhibition in VTE.TAFI (fibrinolysis inhibitor via fibrin remodeling)Small-molecule inhibitors (e.g. AZD-9684, DS-1040, UK-396,082, S62798). Monoclonal antibodies and nanobodies also created.Phase 2 trials: AZD-9684 – in 58 PE patients, improved lung perfusion and fibrinolysis markers with no bleeding, but development halted. DS-1040 – in 125 submassive PE patients, did not improve outcomes vs. placebo (no added benefit on clot lysis or RV function); development stopped. S62798 – Phase 1 in 56 healthy subjects showed good tolerability, but Phase 2 in PE was discontinued pre-enrollment. UK-396,082 – Phase 1 done, program ended. Overall, TAFI inhibitors accelerate fibrinolysis in lab and animal models, but translating to clinical benefit has been challenging; no active late-stage trials currently.Inhibitors of key fibrinolytic regulators under investigation. By blocking α2-antiplasmin or PAI-1, endogenous fibrinolytic activity (plasmin/tPA) may be enhanced, potentially improving clot resolution in VTE. TAFI inhibitors have also been tested, but none have progressed to Phase 3. The table summarizes representative agents and trial outcomes. As of 2025, α2AP and PAI-1 inhibitors show promise in early trials, whereas TAFI inhibitor development has encountered setbacks Main fibrinolysis regulators and the current status of inhibitors Inhibitors of key fibrinolytic regulators under investigation. By blocking α2-antiplasmin or PAI-1, endogenous fibrinolytic activity (plasmin/tPA) may be enhanced, potentially improving clot resolution in VTE. TAFI inhibitors have also been tested, but none have progressed to Phase 3. The table summarizes representative agents and trial outcomes. As of 2025, α2AP and PAI-1 inhibitors show promise in early trials, whereas TAFI inhibitor development has encountered setbacks Table 3The early clinical efforts to target the leukocyte-vessel wall interaction in VTETargetAgentClinical EvaluationStatus/FindingsLeukocyte PSGL-1 (common ligand for P- and E-selectin)SelK2 (monoclonal antibody to PSGL-1)Tested for VTE prophylaxis in orthopedic surgery (COURSE trial, n = 207, vs. enoxaparin).Completed. Results pending publication. Aim was to reduce postoperative DVT by preventing leukocyte-driven thrombosis. No safety concerns reported in trial registry (expected lower bleeding due to no direct anticoagulant effect).E-selectinon endotheliumUproleselan (GMI-1271) (small-molecule E-selectin antagonist)Phase 1 in healthy volunteers completed; Pilot Phase 2 in distal DVT (NCT02744833) started but discontinued after 2 patients.Phase 1: Showed favorable safety, no significant adverse events. DVT trial: Inconclusive (stopped early). Ongoing phase 3 trials in AML for oncology use may provide more safety data. Rationale remains strong for reducing thrombo-inflammation in DVT.P-selectin on endothelium/plateletsCrizanlizumab (monoclonal antibody to P-selectin) – not yet in VTE trials, clinical use in sickle cell disease.No VTE-specific trials yet; indirect evidence from cancer studies (elevated soluble P-selectin predicts thrombosis). Being considered for study in CAT or prevention of IV catheter thrombosis.Preclinical: P-selectin blockade reduces experimental thrombosis and vein wall fibrosis. Clinical hypothesis: Could benefit cancer patients or others with high thrombo-inflammatory drive. No data in VTE patients as of 2025.Anti-inflammatory strategies targeting leukocyte–vessel wall interactions in VTE. Agents blocking PSGL-1 or selectins aim to prevent leukocyte recruitment to the thrombus, thereby reducing coagulation amplification and vein wall inflammation. Clinical evaluation is in early stages; a completed trial of a PSGL-1 antibody and preliminary tests of an E-selectin antagonist are noted. P-selectin inhibition has strong rationale but awaits direct testing in VTE Table 3The early clinical efforts to target the leukocyte-vessel wall interaction in VTETargetAgentClinical EvaluationStatus/FindingsLeukocyte PSGL-1 (common ligand for P- and E-selectin)SelK2 (monoclonal antibody to PSGL-1)Tested for VTE prophylaxis in orthopedic surgery (COURSE trial, n = 207, vs. enoxaparin).Completed. Results pending publication. Aim was to reduce postoperative DVT by preventing leukocyte-driven thrombosis. No safety concerns reported in trial registry (expected lower bleeding due to no direct anticoagulant effect).E-selectinon endotheliumUproleselan (GMI-1271) (small-molecule E-selectin antagonist)Phase 1 in healthy volunteers completed; Pilot Phase 2 in distal DVT (NCT02744833) started but discontinued after 2 patients.Phase 1: Showed favorable safety, no significant adverse events. DVT trial: Inconclusive (stopped early). Ongoing phase 3 trials in AML for oncology use may provide more safety data. Rationale remains strong for reducing thrombo-inflammation in DVT.P-selectin on endothelium/plateletsCrizanlizumab (monoclonal antibody to P-selectin) – not yet in VTE trials, clinical use in sickle cell disease.No VTE-specific trials yet; indirect evidence from cancer studies (elevated soluble P-selectin predicts thrombosis). Being considered for study in CAT or prevention of IV catheter thrombosis.Preclinical: P-selectin blockade reduces experimental thrombosis and vein wall fibrosis. Clinical hypothesis: Could benefit cancer patients or others with high thrombo-inflammatory drive. No data in VTE patients as of 2025.Anti-inflammatory strategies targeting leukocyte–vessel wall interactions in VTE. Agents blocking PSGL-1 or selectins aim to prevent leukocyte recruitment to the thrombus, thereby reducing coagulation amplification and vein wall inflammation. Clinical evaluation is in early stages; a completed trial of a PSGL-1 antibody and preliminary tests of an E-selectin antagonist are noted. P-selectin inhibition has strong rationale but awaits direct testing in VTE The early clinical efforts to target the leukocyte-vessel wall interaction in VTE E-selectin on endothelium Anti-inflammatory strategies targeting leukocyte–vessel wall interactions in VTE. Agents blocking PSGL-1 or selectins aim to prevent leukocyte recruitment to the thrombus, thereby reducing coagulation amplification and vein wall inflammation. Clinical evaluation is in early stages; a completed trial of a PSGL-1 antibody and preliminary tests of an E-selectin antagonist are noted. P-selectin inhibition has strong rationale but awaits direct testing in VTE